Advertisement

Topics

Companies Related to "Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib" [Most Relevant Company Matches] RSS

08:01 EDT 17th October 2018 | BioPortfolio

Here are the most relevant search results for "Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib" found in our extensive corporate database of over 50,000 company records.

Showing "Trial Evaluate Improvement Chronic grade Patients With With" Companies 1–25 of 5,300+

Relevant

Valentis

Valentis is a biotechnology company that was engaged in the development of innovative products for peripheral arterial disease (PAD), a large and unsatisfied market. On July 11, 2006 Valentis announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in PAD. The primary efficacy endpoint in t...


SanBio Co., Ltd.

SanBio (TOKYO:4592) is a leading regenerative medical products company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. The company has completed enrollment for and is conducting a Phase 2b clinical trial for its proprietary regenerative medical product SB623 for ...

Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders. Synergy’s lead drug, plecanatide, and next generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate ...


Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical tri...

Phytel

The premier company empowering physician-led health improvement, Phytel provides physicians with proven technology to deliver timely, coordinated care to their patients. Phytel’s state-of-the-art registry, which now encompasses 15 million patients nationwide, uses evidence-based chronic and preventive care protocols to identify and notify patients due...

Protalex, Inc.

Protalex, Inc. is a clinical stage biopharmaceutical company that is developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including but not limited to, rheumatoid arthritis. Protalex’s lead product PRTX-100, which is formulated with a highly-purified form of staphylococcal protein A, has completed a Phase 1b...

Aurinia Pharmaceuticals Inc.

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal d...

Ario Pharma Ltd

ario pharma ltd focusses on the development of drugs for the treatment of respiratory indications. Ario is about to evaluate the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase 2 clinical trials that will read out in 2014. The company is managed by a highly experienced development team and supported by world-renowned KOLs in respiratory disease. Co...

Intersect ENT, Inc. '

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new ste...

Akili Interactive Labs, Inc.

Akili is building clinically-validated cognitive treatments and assessments that are delivered in an action video game interface. Leveraging medical-grade science and consumer-grade software technology, the company is seeking to produce a new type of medical product that can offer safe and effective scalable treatment and better monitoring for pa...

Provisio, Inc

Headquartered in Nashville, TN, Provisio, Inc. develops technologies and services that enhance clinical trial processes. Its flagship solution, iTrials, automates and streamlines the way drug trial candidates are identified, notified and enrolled. iTrials breaks the traditional paradigm associated with lengthy and costly clinical trial enrollment. Leveraging iTrials "unique-to-industry" data wareh...

LifeWave Ltd

Incorporated in 2000, LifeWave Ltd. is a premier provider of innovative medical device in the field of Advanced Wound Management. The Company has developed an extensively researched and clinically-validated product that represents a truly novel approach in addressing the critical medical issue of chronic wounds care. LifeWave is currently focused on introducing its product to global markets. Chron...

Sinexus, Inc.

Sinexus, Inc. (http://www.sinexusinc.com) is a development-stage medical device company that is pioneering novel therapies for Ear, Nose & Throat (ENT) physicians to utilize in providing improved treatment for their patients. Sinexus' initial focus is treating patients with Chronic Rhinosinusitis, a debilitating chronic condition that affects one out of seven adults in the United States.

Evaluate Ltd.

Established in 1996, Evaluate Ltd. is the leader in high quality life science sector analysis. EvaluatePharma delivers exclusive consensus forecasts and trusted commercial insight into biotech and pharmaceutical performance. EvaluateMedTech sets a new standard in integrated analysis and consensus forecasts of the global medical device and diagnostic indust...

The Partnership to Fight Chronic Disease New Jersey

The Partnership to Fight Chronic Disease (PFCD) is an internationally-recognized NGO of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease. For a collection of statistics and commentary o...

Evaluate, Ltd.

Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Evaluate supports life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Its services include EvaluatePharma, EvaluateClinicalTrials and EvaluateMedTe...

Tricida, Inc.

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Tricida has successfully...

Bosch Healthcare Systems, Inc.

Robert Bosch Healthcare Systems, Inc., is a leading provider of innovative telehealth systems. Bosch’s product spectrum ranges from patient interfaces to comprehensive health management and patient evaluation software allowing healthcare professionals to efficiently evaluate the patient’s health status. Bosch Healthcare strives to help improve di...

Vicus Therapeutics, LLC

Vicus Therapeutics is a biopharmaceutical company dedicated to bringing breakthrough therapies to patients with cancer. Vicus' lead investigational therapy, VT-122, is a combination of etodolac and propranolol. VT-122 showed positive results in a Phase 2 clinical trial of lung cancer patients and is currently being evaluated in a Phase 2 clinical trial of liver cancer patients receiving Nexavar ...

Robert Bosch Healthcare Systems, Inc.

Robert Bosch Healthcare Systems, Inc., is a leading provider of innovative telehealth systems. Bosch’s product spectrum ranges from patient interfaces to comprehensive health management and patient evaluation software allowing healthcare professionals to efficiently evaluate the patient’s health status. Bosch Healthcare strives to help improve di...

Antidote Technologies Ltd

Antidote is a digital health company on a mission to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need it. In a world where 80% of clinical trials are delayed or closed due to lack of participants, Antidote use cutting-edge technology to match the right patients with the right trials. Antido...

Life Time Pharmaceuticals Incorporated

LifeTime™ Pharmaceuticals, a private clinical-stage pharmaceutical company, focuses on the development of drugs that are safe enough for long-term, chronic administration. Compounds currently under development seek to eliminate and prevent recurrence of potentially fatal cancers and infectious syndromes. Human clinical trial results presented at several scientific meetings (see below) have shown...

Iinvivodata

invivodata is the worldwide leader in capturing clinical trial data of the highest integrity directly from patients. With a unique combination of scientific, technological, and regulatory expertise, invivodata has pioneered the evolution of the electronic Patient Reported Outcomes (ePRO) industry and continues to provide innovative methods that make it easy for clinical trial sponsors to attain th...

Pharos Innovations

Founded in 1995, Pharos Innovations assists healthcare providers and payers in achieving next generation clinical and financial performance improvement. An innovative, device-free platform, Tel-Assurance(R), improves care coordination and drives dramatic clinical improvement and cost savings by remotely monitoring patients and averting unnecessary clinical events. Our enabling technologies proacti...

MEDai, Inc.

MEDai, Inc. is a leading health information company offering award-winning solutions for the improvement of healthcare delivery. Utilizing cutting-edge technology, payors and care management organizations are able to predict patients at risk, identify cost drivers for their high-risk population, forecast future health plan costs, evaluate patient patterns over time, and improve outcomes. For more ...


More From BioPortfolio on "Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks